• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
GSK-1120212

GSK-1120212

Product ID G7440
Cas No. 871700-17-3
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $78.80 In stock
25 mg $102.90 In stock
100 mg $183.80 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

GSK-1120212 inhibits MEK1/2 and is currently in clinical trials as a potential treatment for melanoma. GSK-1120212 exhibits anticancer chemotherapeutic activity, upregulating p27 expression and inhibiting growth in colorectal cancer cells and suppressing tumor growth in colorectal cancer xenografts.

Product Info

Cas No.

871700-17-3

Purity

≥98%

Formula

C26H23FlN5O4

Formula Wt.

615.39

IUPAC Name

N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide

Synonym

Trametinib, JTP-74057

Solubility

DMSO (10 mg/ml) Water Insoluble Ethanol Insoluble

Appearance

White Powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

G7440 MSDS PDF

Info Sheet

G7440 Info Sheet PDF

Brochures

Ras-Raf-MEK-ERK Pathway Booklet

References

Hartsough EJ, Basile K, Aplin AE. Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant-expressing Melanoma. Mol Cancer Res. 2014 Feb 11. [Epub ahead of print]. PMID: 24520098.

Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 1;31(4):482-9. PMID: 23248257.

Yamaguchi T, Kakefuda R, Tajima N, et al. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol. 2011 Jul;39(1):23-31. PMID: 21523318.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • E5568

    Enramycin A

    Polypeptide; peptidoglycan inhibitor.

    ≥95%
  • C5645

    Colchicine

    Found in Colchicum; microtubule polymerization ...

    ≥97%
  • I0502

    Ibandronate Sodium Monohydrate

    Bisphosphonate.

    ≥98%
  • G3453

    20(S)-Ginsenoside Rh2

    Triterpene saponin found in Panax.

    ≥98%
  • A6804

    Arbutin

    Glycoside hydroquinone originally found in Berg...

    ≥98%
  • N1721

    Nefiracetam

    Pyrrolidone; NMDA and mGluR5 agonist, N-type an...

    ≥98%
  • V014451

    Valiltramiprosate

    beta-Amyloid anti-oligomer and aggregation inhi...

    ≥99%
  • D1768

    Dermaseptin I

    Cationic antimicrobial peptide, alters bacteria...

    ≥96%
  • S0459

    SB-590885

    B-Raf inhibitor.

    ≥97%
  • B4976

    BMS-794833

    MET, VEGFR2, Ron, Axl, FLT3 inhibitor.

    ≥98%
  • C4558

    Clonidine Hydrochloride

    Imidazoline and α2-adrenergic agonist, Nav1.7 ...

    ≥98%
  • C0156

    9-Nitro-20S-camptothecin

    Camptothecin derivative; topoisomerase I inhibi...

    ≥98%
  • C211324

    CFI-400945

    PLK4 inhibitor.

    ≥98%
  • B9700

    BYL719

    p110α PI3K inhibitor.

    ≥99%, ≥99%ee
  • K040009

    KB-0742 dihydrochloride

    CDK9 inhibitor.

    ≥99%
  • C9612

    Cyclosporin C

    Cyclosporin metabolite; weak calmodulin inhibit...

    ≥98%
  • L3561

    D,L-α-Lipoic Acid

    Endogenous organosulfur also found in meat and ...

    ≥99%
  • A760010

    AT-121

    Biofunctional NOP/MOP receptor agonist

    ≥98%
  • T1012

    13-TES-Baccatin III

    Synthesis impurity

    ≥98%
  • G691343

    Griseofulvin

    Fungistatic

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only